• IONIS-HTT Rx Granted PRIME Designation by the European Medicines Agency americanpharmaceuticalreview
    August 06, 2018
    Ionis announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to IONIS-HTTRx (also known as RG6042) for the treatment of people with Huntington's disease (HD). IONIS-HTTRx is the first drug to demonstrate reduction
PharmaSources Customer Service